



The IU Health Blood Bank is introducing pathogen-reduced; psoralen-treated platelets in 2021. Contraindications and warnings have been reviewed, and this product is safe and effective for our patients receiving platelet therapy.

The INTERCEPT Blood System (Psoralen Treatment) Pathogen Reduction System:

- o Reduces risk of transfusion-transmitted infection (TTI), including sepsis, in platelet recipients.
- o FDA approved alternative to Zika and Babesia testing requirements.
- o Effective approach to preventing CMV transmission.⁶ Platelets that have been INTERCEPT treated **do not require additional CMV serology.**
- o Reduces the number of T-cells (Leukocytes) in platelets, and is FDA approved. Platelets that have been INTERCEPT treated **do not need to be irradiated.**


PSORALEN TREATED PLATELET ADMINISTRATION

- o Platelet dosing -same as conventional platelet products.
- o Pre-medication and hang time -same as conventional platelet products.
- o Patients may receive both conventional platelets and psoralen treated platelets to fill their transfusion requirements.
- o Psoralen treated platelets can be hung in the same line as conventional platelets provided the tubing has not expired.

CONVENTIONAL PLATELET vs. PSORALEN-TREATED PLATELET



PSORALEN-TREATED labels indicate this product has undergone the psoralen + UVA light treatment to inactivate pathogens.



PSORALEN TREATMENT of platelets is an FDA approved alternative to IRRADIATION of platelets.

PSORALEN TREATMENT also meets AABB CMV Mitigation Standards

PSORALEN-TREATED platelet products are functionally equivalent to conventional platelets.